- Home
- AIIO vs IMUX Comparison
AIIO vs IMUX Comparison
Compare AIIO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIO | IMUX |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.6M | 85.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AIIO | IMUX |
|---|---|---|
| Price | $0.31 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 5.3M | 1.5M |
| Earning Date | 02-02-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.52 |
| 52 Week High | $3.48 | $1.39 |
Technical Indicators
Market Signals| Indicator | AIIO | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 30.01 | 29.05 |
| Support Level | $0.30 | $0.55 |
| Resistance Level | $0.35 | $0.60 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.64 | 2.01 |
Price Performance
Historical ComparisonAbout AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.